[go: up one dir, main page]

EP4204004A4 - Compositions anti-idiotype et procédés d'utilisation associés - Google Patents

Compositions anti-idiotype et procédés d'utilisation associés Download PDF

Info

Publication number
EP4204004A4
EP4204004A4 EP21862987.1A EP21862987A EP4204004A4 EP 4204004 A4 EP4204004 A4 EP 4204004A4 EP 21862987 A EP21862987 A EP 21862987A EP 4204004 A4 EP4204004 A4 EP 4204004A4
Authority
EP
European Patent Office
Prior art keywords
methods
idiotype
compositions
idiotype compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21862987.1A
Other languages
German (de)
English (en)
Other versions
EP4204004A1 (fr
Inventor
Gregory Ian Frost
Gregory Harold SCHREIBER
Anirban Kundu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exuma Biotech Corp
Original Assignee
Exuma Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/048843 external-priority patent/WO2021042072A1/fr
Priority claimed from PCT/US2021/020922 external-priority patent/WO2021178701A1/fr
Application filed by Exuma Biotech Corp filed Critical Exuma Biotech Corp
Publication of EP4204004A1 publication Critical patent/EP4204004A1/fr
Publication of EP4204004A4 publication Critical patent/EP4204004A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP21862987.1A 2020-08-31 2021-08-31 Compositions anti-idiotype et procédés d'utilisation associés Pending EP4204004A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2020/048843 WO2021042072A1 (fr) 2019-09-01 2020-08-31 Méthodes et compositions pour la modification et l'administration de lymphocytes
US202163136177P 2021-01-11 2021-01-11
US202163200329P 2021-03-01 2021-03-01
PCT/US2021/020922 WO2021178701A1 (fr) 2020-03-05 2021-03-04 Méthodes et compositions pour l'administration d'agrégats de lymphocytes modifiés
PCT/US2021/048532 WO2022047417A1 (fr) 2020-08-31 2021-08-31 Compositions anti-idiotype et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
EP4204004A1 EP4204004A1 (fr) 2023-07-05
EP4204004A4 true EP4204004A4 (fr) 2024-11-27

Family

ID=80354145

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21862987.1A Pending EP4204004A4 (fr) 2020-08-31 2021-08-31 Compositions anti-idiotype et procédés d'utilisation associés

Country Status (3)

Country Link
EP (1) EP4204004A4 (fr)
CN (1) CN116249559A (fr)
WO (1) WO2022047417A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2022187289A1 (fr) * 2021-03-01 2022-09-09 Exuma Biotech Corp. Procédés et compositions pour l'administration de particules rétrovirales
WO2023196947A2 (fr) * 2022-04-07 2023-10-12 Board Of Regents, The University Of Texas System Procédés d'activation et d'expansion de cellules tueuses naturelles modifiées et combinaisons avec des anticorps

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802374B2 (en) * 2009-11-03 2014-08-12 City Of Hope Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
WO2018226897A1 (fr) * 2017-06-07 2018-12-13 Intrexon Corporation Expression de nouvelles étiquettes de cellules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
KR20230172625A (ko) * 2014-08-28 2023-12-22 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
US11155622B2 (en) * 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
US20200255864A1 (en) * 2016-03-19 2020-08-13 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
WO2020150702A1 (fr) * 2019-01-18 2020-07-23 University Of Southern California Méthodes et compositions pour améliorer la sécurité et l'efficacité de thérapies cellulaires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802374B2 (en) * 2009-11-03 2014-08-12 City Of Hope Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
WO2018226897A1 (fr) * 2017-06-07 2018-12-13 Intrexon Corporation Expression de nouvelles étiquettes de cellules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022047417A1 *

Also Published As

Publication number Publication date
EP4204004A1 (fr) 2023-07-05
CN116249559A (zh) 2023-06-09
WO2022047417A1 (fr) 2022-03-03

Similar Documents

Publication Publication Date Title
EP3976638A4 (fr) Compositions d'il-2 et leurs méthodes d'utilisation
EP4022059A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3959318A4 (fr) Compositions d'oligonucléotides et leurs méthodes d'utilisation
EP3965780A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
IL309073A (en) Enantiomeric entactogen compounds and methods of their use.
EP3997115A4 (fr) Compositions d'il-2 et leurs procédés d'utilisation
EP4103662A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP4204004A4 (fr) Compositions anti-idiotype et procédés d'utilisation associés
EP4127088A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP4121224A4 (fr) Compositions de nettoyage et leurs procédés d'utilisation
EP3917543A4 (fr) Compositions de nitrate améliorées et procédés d'utilisation
EP4204506A4 (fr) Compositions de nettoyage et leurs procédés d'utilisation
EP4110369A4 (fr) Méthodes de traitement et compositions associées
GB202319843D0 (en) CAS13-based compositions and methods of use thereof
EP4081231A4 (fr) Compositions comprenant des microbes et leurs procédés d'utilisation et de fabrication
EP4103663A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP4045226A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP4142740A4 (fr) Compositions et leurs méthodes d'utilisation
AU2021343471A9 (en) Chemical compositions and methods of using the same
EP4381022A4 (fr) Compositions et leurs procédés d'utilisation
EP4054514A4 (fr) Compositions contenant des fenchols et procédés d'utilisation
EP4110384A4 (fr) Compositions comprenant des vaccins à auto-assemblage et leurs méthodes d'utilisation
IL312928A (en) Complement Factor B Modulating Preparations and Methods for Using Them
EP4216938A4 (fr) Compositions et méthodes de traitement de la chute de cheveux et autres états
IL311518A (en) Preparations that modulate perkalkerine and methods of using them

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039395000

Ipc: C07K0014725000

A4 Supplementary search report drawn up and despatched

Effective date: 20241025

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/62 20060101ALI20241021BHEP

Ipc: C07K 16/42 20060101ALI20241021BHEP

Ipc: C07K 16/28 20060101ALI20241021BHEP

Ipc: C07K 14/725 20060101AFI20241021BHEP